

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

Reference is made to the notice (the “**Original Notice**”) of the annual general meeting (the “**Meeting**”) of Biosino Bio-Technology and Science Incorporation (the “**Company**”) dated 6 June 2024, which sets out the resolutions to be considered and, if thought fit, to be approved at the Meeting to be held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the People's Republic of China (the “**PRC**”) on Friday, 28 June 2024 at 10:00 a.m.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the Meeting will be held as originally scheduled at the same time and venue. In addition to the resolutions contained in the Original Notice, the following new resolutions will also be considered and approved, if thought fit, at the Meeting. This supplemental notice should be read in conjunction with the Original Notice:

AS ORDINARY RESOLUTIONS

- 5A. To consider and approve the appointment of Dr. He Xin as an independent non-executive director of the Company (the “**Director(s)**”), and authorise the board (the “**Board**”) of Directors to fix her remuneration and to enter into service contract with her subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters.
- 5B. To consider and approve the appointment of Mr. Fan Hua as a supervisor of the Company and authorise the Board to fix his remuneration and to enter into service contract with him subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Tung Woon Cheung, Eric
Company Secretary

Beijing, the PRC, 18 June 2024

Notes:

- i. A member of the Company (“**Member**”) entitled to attend and vote at the Meeting is entitled to appoint a proxy or proxies to attend and vote in his stead. A proxy needs not be a Member. A revised form of proxy (the “**Revised Proxy Form**”) for use at the Meeting is enclosed herewith. In the case of the joint holders of any Share, only the person whose name appears first in the register of members shall be entitled to receive this supplemental notice, to attend and exercise all the voting powers attached to such share at the Meeting, and this supplemental notice shall be deemed to be given to all joint holders of such share.
- ii. To be valid, the Revised Proxy Form together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power of attorney or authority must be deposited with the Company’s H share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, and in case of holders of domestic shares, to the Company’s mailing address at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC, postal code 102200, not later than 24 hours before the time appointed for holding the Meeting or the time appointed for passing the resolutions or any adjournment thereof. Delivery of the Revised Proxy Form shall not preclude a Member from attending and voting in person at the Meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
- iii. Members and their proxies should produce identity proof (and form of proxy in case of proxies) when attending the Meeting.
- iv. It is expected that the Meeting will last not more than half a day. Members and their proxies attending the Meeting shall bear their own travel and accommodation expenses.
- v. If you wish to appoint a proxy to attend and vote at the Meeting on your behalf and if you have not yet returned the first proxy form (the “**First Proxy Form**”) issued on 6 June 2024, you should complete, sign and return the accompanying Revised Proxy Form to Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 24 hours before the time appointed for holding the Meeting or any of its adjournments (as the case may be) (the “**Closing Time**”). In this case, the First Proxy Form should not be submitted.
- vi. If you wish to appoint a proxy to attend and vote at the Meeting on your behalf, and have already duly completed and submitted the First Proxy Form to the Company, you should note that:
 - (a) if no Revised Proxy Form is submitted to the Company, the First Proxy Form correctly completed and duly lodged will be treated as a valid proxy form submitted by you. The proxy so appointed shall be required to vote in such manner as he/she may be directed under the First Proxy Form and, in respect of the resolutions set out in this supplemental notice, the proxy will be entitled to vote at his/her discretion or to abstain from voting on such resolutions;
 - (b) if the Revised Proxy Form is duly completed and submitted by the Closing Time, such Revised Proxy Form will revoke and supersede the First Proxy Form submitted by you. Such Revised Proxy Form will be treated as a valid proxy form submitted by you; and
 - (c) if the Revised Proxy Form is submitted after the Closing Time, such Revised Proxy Form will be invalid and the validity of the First Proxy Form correctly completed and duly submitted by you will not be affected. The proxy appointed by you under the First Proxy Form (if duly completed) will be entitled to vote in the manner as mentioned in (a), as if the Revised Proxy Form is not lodged.

As at the date of this notice, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors

Mr. Yang Peng (楊鵬先生) and Mr. Chen Zhengyong (陳正永先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangan (沈劍剛教授)

This notice, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this notice is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this notice misleading.

This notice will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.